dalteparin has been researched along with Pre-Eclampsia in 21 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Pre-Eclampsia: A complication of PREGNANCY, characterized by a complex of symptoms including maternal HYPERTENSION and PROTEINURIA with or without pathological EDEMA. Symptoms may range between mild and severe. Pre-eclampsia usually occurs after the 20th week of gestation, but may develop before this time in the presence of trophoblastic disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Between August 1 2000 and June 20 2007, 116 pregnant women with: (i) | 9.14 | Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. ( David, M; Demers, C; Garneau, P; Gauthier, R; Kahn, SR; Leduc, L; Magee, LA; Michon, N; Morin, F; Rey, E; Rodger, M, 2009) |
| "To evaluate the benefit of treatment with dalteparin and low-dose aspirin (ASA) in the prevention of obstetric complications in women with inherited thrombophilia." | 7.74 | Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. ( David, M; Dubois, E; Leduc, L; Rey, E; Takser, L, 2007) |
| "Between August 1 2000 and June 20 2007, 116 pregnant women with: (i) | 5.14 | Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. ( David, M; Demers, C; Garneau, P; Gauthier, R; Kahn, SR; Leduc, L; Magee, LA; Michon, N; Morin, F; Rey, E; Rodger, M, 2009) |
| "To evaluate the benefit of treatment with dalteparin and low-dose aspirin (ASA) in the prevention of obstetric complications in women with inherited thrombophilia." | 3.74 | Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. ( David, M; Dubois, E; Leduc, L; Rey, E; Takser, L, 2007) |
| "Preeclampsia (PE) and intrauterine growth restriction (IUGR) are major causes of maternal and perinatal morbidity and mortality." | 2.94 | Early Prophylactic Enoxaparin for the Prevention of Preeclampsia and Intrauterine Growth Restriction: A Randomized Trial. ( Alijotas-Reig, J; Bella, M; Burgos, J; Cabero, L; Carreras, E; De Diego, R; Gómez-Roig, MD; Llurba, E; Martínez-Astorquiza, T; Mazarico, E; Sánchez, O; Sánchez-Durán, MÁ, 2020) |
| "Aspirin and heparin have been shown to have potentially beneficial effects on trophoblast implantation." | 2.79 | Low dose aspirin and low-molecular-weight heparin in the treatment of pregnant Libyan women with recurrent miscarriage. ( Adam, I; Ashur, BM; Elbareg, AM; Elmahashi, MO; Essadi, FM, 2014) |
| "In treated women, the relative risk for preeclampsia was 0." | 2.71 | Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. ( Abbate, R; Fatini, C; Gensini, F; Gensini, GF; Marchionni, M; Mello, G; Parretti, E; Riviello, C; Scarselli, GF, 2005) |
| "Compared with control intervention for recurrent miscarriage, enoxaparin treatment has no substantial influence on live births (RR = 1." | 2.61 | Enoxaparin (or plus aspirin) for the prevention of recurrent miscarriage: A meta-analysis of randomized controlled studies. ( Chen, Y; Cheng, X; Li, N; Lin, T; Sheng, X, 2019) |
| "Women with thrombophilia have an increased risk of pregnancy loss and possibly other serious obstetric complications, although definition of the magnitude of risk will require prospective longitudinal studies." | 2.42 | Thrombophilia and pregnancy complications. ( Kujovich, JL, 2004) |
| "Human pregnancy is associated with a mild proinflammatory state characterized by circulatory neutrophil activation which is further increased in complicated pregnancies, placenta-mediated complications being associated with an increased thrombotic risk." | 1.62 | NETosis Markers in Pregnancy: Effects Differ According to Histone Subtypes. ( Bouvier, S; Demattei, C; Fortier, M; Gris, JC; Herzog, M; Letouzey, V; Mercier, E; Mousty, E; Nouvellon, E; Rommelaere, G; Vincent, L, 2021) |
| "Preeclampsia is a serious hypertensive disorder of pregnancy, which is only cured with delivery of the placenta, thereby commonly necessitating preterm birth of the fetus." | 1.56 | The antithrombin binding regions of heparin mediate fetal growth and reduced placental damage in the RUPP model of preeclampsia†. ( Baczyk, D; Kingdom, JC; Wat, JM, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 7 (33.33) | 24.3611 |
| 2020's | 6 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Myasnikova, VV | 2 |
| Galenko-Yaroshevskii, PA | 2 |
| Lysenkov, SP | 2 |
| Gigineishvili, MA | 1 |
| Berberashvili, TM | 1 |
| Kupreishvili, VZ | 1 |
| Rizhvadze, MR | 1 |
| Sukoyan, GV | 1 |
| Tersigni, C | 1 |
| Maulucci, G | 1 |
| Castellani, R | 1 |
| Bianchetti, G | 1 |
| Onori, M | 1 |
| Franco, R | 1 |
| Barbaro, G | 1 |
| De Spirito, M | 1 |
| Lanzone, A | 1 |
| Scambia, G | 1 |
| Di Simone, N | 1 |
| Rahnemaei, FA | 1 |
| Fashami, MA | 1 |
| Abdi, F | 1 |
| Abbasi, M | 1 |
| Bouvier, S | 1 |
| Fortier, M | 1 |
| Vincent, L | 1 |
| Demattei, C | 1 |
| Mousty, E | 1 |
| Herzog, M | 1 |
| Rommelaere, G | 1 |
| Nouvellon, E | 1 |
| Mercier, E | 1 |
| Letouzey, V | 1 |
| Gris, JC | 3 |
| Llurba, E | 1 |
| Bella, M | 1 |
| Burgos, J | 1 |
| Mazarico, E | 1 |
| Gómez-Roig, MD | 1 |
| De Diego, R | 1 |
| Martínez-Astorquiza, T | 1 |
| Alijotas-Reig, J | 1 |
| Sánchez-Durán, MÁ | 1 |
| Sánchez, O | 1 |
| Carreras, E | 1 |
| Cabero, L | 1 |
| Lin, T | 1 |
| Chen, Y | 1 |
| Cheng, X | 1 |
| Li, N | 1 |
| Sheng, X | 1 |
| Liu, Y | 1 |
| Shan, N | 1 |
| Yuan, Y | 1 |
| Tan, B | 1 |
| Che, P | 1 |
| Qi, H | 1 |
| Elmahashi, MO | 1 |
| Elbareg, AM | 1 |
| Essadi, FM | 1 |
| Ashur, BM | 1 |
| Adam, I | 1 |
| Mastrolia, SA | 1 |
| Novack, L | 1 |
| Thachil, J | 1 |
| Rabinovich, A | 1 |
| Pikovsky, O | 1 |
| Klaitman, V | 1 |
| Loverro, G | 1 |
| Erez, O | 1 |
| Salim, R | 1 |
| Nachum, Z | 1 |
| Gavish, I | 1 |
| Romano, S | 1 |
| Braverman, M | 1 |
| Garmi, G | 1 |
| Haddad, B | 2 |
| Winer, N | 1 |
| Chitrit, Y | 1 |
| Houfflin-Debarge, V | 1 |
| Chauleur, C | 2 |
| Bages, K | 1 |
| Tsatsaris, V | 1 |
| Benachi, A | 1 |
| Bretelle, F | 1 |
| Bastuji-Garin, S | 1 |
| Molinari, N | 1 |
| Marès, P | 1 |
| Fabbro-Peray, P | 1 |
| Quéré, I | 1 |
| Lefrant, JY | 1 |
| Dauzat, M | 1 |
| Kujovich, JL | 1 |
| Wat, JM | 2 |
| Baczyk, D | 2 |
| Kingdom, JC | 2 |
| Hawrylyshyn, K | 1 |
| Greig, IR | 1 |
| Rey, E | 2 |
| Garneau, P | 1 |
| David, M | 2 |
| Gauthier, R | 1 |
| Leduc, L | 2 |
| Michon, N | 1 |
| Morin, F | 1 |
| Demers, C | 1 |
| Kahn, SR | 1 |
| Magee, LA | 1 |
| Rodger, M | 1 |
| Stone, S | 1 |
| Hunt, BJ | 1 |
| Seed, PT | 1 |
| Parmar, K | 1 |
| Khamashta, MA | 1 |
| Poston, L | 1 |
| Mello, G | 1 |
| Parretti, E | 1 |
| Fatini, C | 1 |
| Riviello, C | 1 |
| Gensini, F | 1 |
| Marchionni, M | 1 |
| Scarselli, GF | 1 |
| Gensini, GF | 1 |
| Abbate, R | 1 |
| Dubois, E | 1 |
| Takser, L | 1 |
| Herzog, S | 1 |
| Rath, W | 1 |
| Kuhn, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Low Dose Aspirin and Low-molecular-weight Heparin in the Treatment of Pregnant Libyan Women With Recurrent Miscarriage[NCT01917799] | Phase 4 | 150 participants (Anticipated) | Interventional | 2009-01-31 | Recruiting | ||
| Dose Adjusting Enoxaparin Thromboprophylaxis Dosage According to Anti-factor Xa Plasma Levels Improve Pregnancy Outcome[NCT01068795] | 144 participants (Actual) | Interventional | 2009-07-31 | Completed | |||
| Low Molecular Weight Heparin, Enoxaparin, to Prevent Adverse Maternal and Perinatal Outcomes in Women With Previous Severe Preeclampsia at Less Than 34 Weeks' Gestation. A Prospective Randomized Trial[NCT00986765] | Phase 3 | 257 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for dalteparin and Pre-Eclampsia
| Article | Year |
|---|---|
Factors effective in the prevention of Preeclampsia:A systematic review.
Topics: Arginine; Calcium; Drug Therapy, Combination; Enoxaparin; Female; Folic Acid; Heparin, Low-Molecular | 2020 |
Enoxaparin (or plus aspirin) for the prevention of recurrent miscarriage: A meta-analysis of randomized controlled studies.
Topics: Abortion, Habitual; Anticoagulants; Aspirin; Enoxaparin; Female; Humans; Live Birth; Pre-Eclampsia; | 2019 |
The efficacy of enoxaparin for recurrent abortion: a meta-analysis of randomized controlled studies.
Topics: Abortion, Habitual; Enoxaparin; Female; Humans; Infant, Newborn; Live Birth; Pre-Eclampsia; Pregnanc | 2021 |
LMWH in the prevention of preeclampsia and fetal growth restriction in women without thrombophilia. A systematic review and meta-analysis.
Topics: Enoxaparin; Female; Fetal Growth Retardation; Heparin, Low-Molecular-Weight; Humans; Pre-Eclampsia; | 2016 |
Thrombophilia and pregnancy complications.
Topics: Abortion, Habitual; Enoxaparin; Factor V; Female; Fetal Growth Retardation; Fibrinolytic Agents; Hum | 2004 |
7 trials available for dalteparin and Pre-Eclampsia
| Article | Year |
|---|---|
Early Prophylactic Enoxaparin for the Prevention of Preeclampsia and Intrauterine Growth Restriction: A Randomized Trial.
Topics: Enoxaparin; Female; Fetal Growth Retardation; Heparin, Low-Molecular-Weight; Humans; Infant, Newborn | 2020 |
Low dose aspirin and low-molecular-weight heparin in the treatment of pregnant Libyan women with recurrent miscarriage.
Topics: Abortion, Habitual; Adult; Aspirin; Birth Weight; Embryo Implantation; Enoxaparin; Female; Fibrinoly | 2014 |
Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial.
Topics: Adult; Anticoagulants; Birth Weight; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Infant, Newbo | 2016 |
Enoxaparin and Aspirin Compared With Aspirin Alone to Prevent Placenta-Mediated Pregnancy Complications: A Randomized Controlled Trial.
Topics: Abruptio Placentae; Adult; Aspirin; Drug Therapy, Combination; Enoxaparin; Female; Humans; Pre-Eclam | 2016 |
Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial.
Topics: Anticoagulants; Aspirin; Cohort Studies; Disease Progression; Enoxaparin; Female; Follow-Up Studies; | 2011 |
Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial.
Topics: Adult; Dalteparin; Female; Fetal Death; Humans; Infant, Low Birth Weight; Infant, Newborn; Pilot Pro | 2009 |
Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women.
Topics: Adult; Anticoagulants; Birth Weight; Circadian Rhythm; Dalteparin; Diastole; Female; Fetal Growth Re | 2005 |
9 other studies available for dalteparin and Pre-Eclampsia
| Article | Year |
|---|---|
Pharmacological correction of hemostasis-regulating function of the lungs in rats with uncomplicated pregnancy and experimental gestosis.
Topics: Animals; Anticoagulants; Birth Weight; Blood Coagulation; Blood Coagulation Disorders; Female; Fetal | 2005 |
Pharmacological correction of changes in the lung-placenta system under experimental conditions.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fibrinogen; Hydrocortison | 2005 |
Enoxaparin Increases D6 Receptor Expression and Restores Cytoskeleton Organization in Trophoblast Cells from Preeclampsia.
Topics: Cytoskeleton; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; Pre-Eclampsia; Pregnancy; T | 2022 |
NETosis Markers in Pregnancy: Effects Differ According to Histone Subtypes.
Topics: Adult; Apoptosis; Aspirin; Cell Line; Cell Movement; Enoxaparin; Extracellular Traps; Female; France | 2021 |
The antithrombin binding regions of heparin mediate fetal growth and reduced placental damage in the RUPP model of preeclampsia†.
Topics: Animals; Anticoagulants; Dalteparin; Female; Fetal Development; Gene Expression Regulation; Heparin; | 2020 |
Effects of glycol-split low molecular weight heparin on placental, endothelial, and anti-inflammatory pathways relevant to preeclampsia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Cell Adhesion; Complement Activation; Dalte | 2018 |
Longitudinal evaluation of markers of endothelial cell dysfunction and hemostasis in treated antiphospholipid syndrome and in healthy pregnancy.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Biomarkers; Dalteparin; Endothelium, Vascular; F | 2003 |
Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia.
Topics: Abruptio Placentae; Adult; Anticoagulants; Aspirin; Dalteparin; Drug Therapy, Combination; Female; F | 2007 |
[Successful therapy of heparin-associated thrombocytopenia with a low sulfated heparinoid].
Topics: Adult; Anticoagulants; Cesarean Section; Chondroitin Sulfates; Cross Reactions; Dalteparin; Dermatan | 1995 |